Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isosorbide mononitrate is a small molecule antianginal agent in the nitrate class used primarily to prevent angina pectoris (chest pain) associated with coronary artery disease. It acts as a prodrug for nitric oxide (NO), which induces vasodilation by relaxing vascular smooth muscle. This process involves activation of soluble guanylyl cyclase in vascular endothelial cells, leading to increased cyclic GMP levels and subsequent smooth muscle relaxation through reduced intracellular calcium concentrations. The result is dilation of both peripheral veins and arteries, reducing cardiac preload and afterload while improving coronary blood flow. Isosorbide mononitrate does not provide immediate relief for acute angina attacks but is effective for long-term prevention[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isosorbide mononitrate.